A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD (AURORA)

• Change from baseline in BCVA [ Time Frame: at 3-month ] [ Designated as safety issue: No ]
• The incidence rate of adverse event [ Time Frame: at 3-month ] [ Designated as safety issue: Yes ]

• best-corrected visual acuity(BCVA) [ Time Frame: BCVA will be assessed over a 3-month treatment period and a 12-month treatment period ] [ Designated as safety issue: No ]
  To evaluate the efficacy of intravitreal injection of KH902 of each group in the mean change from baseline in best-corrected visual acuity (BCVA) over a 3-month treatment period and a 12-month treatment period.
• the change of physical symptoms and signs, the results of lab and other examinations, and incidence rate of adverse event and adverse reaction [ Time Frame: over a 12-month treatment period ] [ Designated as safety issue: Yes ]
  To evaluate the safety of intravitreal injection of KH902 of each group by the change of physical symptoms and signs, the results of lab and other examinations, and incidence rate of adverse event and adverse reaction over a 12-month treatment period.

This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.

AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost.

The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase I study show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.

This study is designed to confirm the efficacy and safety of multiple injections of KH902 at variable dosing regimen in patients with CNV due to neovascular AMD. Based on the characteristics of KH902 and results from KH902 Phase I study as well as reference to clinical trials of similar drugs, it is determined that KH902 is administrated at 0.5mg/eye/time and 2.0mg/eye/time.

• Experimental: 0.5 mg cohort
  patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
  Intervention: Biological: intravitreal injection of KH902
• Experimental: 2.0 mg cohort
  patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
  Intervention: Biological: intravitreal injection of KH902

Inclusion criteria:

• Signed the ICF; Age ≥ 50 years of either gender;
• Active primary or recurrent lesions with subfoveal or juxtafoveal CNV secondary to neovascular AMD in the study eye;
• Lesion size ≤ 12 disc areas in either eye;
• BCVA of the study eyes between 73 and 24 letters, inclusively, and the BCVA of fellow eyes ≥ 19 letters;
• Clear ocular media and adequate pupil dilation.
• If both eyes were eligible, only one was selected.

Exclusion criteria:

• History of vitreous hemorrhage, retinal detachment or macular hole, presence of retinal pigment epithelial tear, retinal macular traction or macular epiretinal membrane, and PCV in the study eye;
• Subfoveal scar or atrophy in the study eye;
• Subretinal hemorrhage in the study eye;
• Uncontrolled glaucoma in either eye;
• Active inflammation or infection in either eye;
• Previous drug treatment, either anti-VEGF drugs or steroid derivatives, and/or, previous ophthalmologic operation or laser therapy in the study eye;
• History of surgery within one month preceding enrollment;
• Any uncontrolled clinical disorders;
• Patients of child-bearing potential do not adopted adequate contraception methods;
• Pregnant or nursing women;
• Patients need to exclude in the opinion of investigator.

• Beijing DMS Pharma Ltd.
• Digital Angiography Reading Center